S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

PVLA Palvella Therapeutics Inc

23.25

2.55 (12.32%)

Last Updated: 13:11:41

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

Palvella Therapeutics (NASDAQ:PVLA)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Palvella Therapeutics Charts.

Palvella Therapeutics (NASDAQ:PVLA)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Palvella Therapeutics Charts.

Palvella Therapeutics Inc News

Form 8-K - Current report
Tuesday 4 March 2025 (1 day ago) • Edgar (US Regulatory)

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
Tuesday 25 February 2025 (1 week ago) • GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans
Tuesday 18 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
Monday 10 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
Monday 10 February 2025 (3 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Friday 7 February 2025 (4 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 7 February 2025 (4 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 7 February 2025 (4 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 7 February 2025 (4 weeks ago) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Friday 17 January 2025 (2 months ago) • Edgar (US Regulatory)

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
Friday 10 January 2025 (2 months ago) • GlobeNewswire Inc.

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Wednesday 8 January 2025 (2 months ago) • Edgar (US Regulatory)

More Palvella Therapeutics Inc News Articles

Vontobel Financial Produ...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions